Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elisa Campi"'
Autor:
Valentina Doldi, Mara Lecchi, Silva Ljevar, Maurizio Colecchia, Elisa Campi, Giovanni Centonze, Cristina Marenghi, Tiziana Rancati, Rosalba Miceli, Paolo Verderio, Riccardo Valdagni, Paolo Gandellini, Nadia Zaffaroni
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 14, p 7987 (2022)
Prostate cancer (PCa) ranges from indolent to aggressive tumors that may rapidly progress and metastasize. The switch to aggressive PCa is fostered by reactive stroma infiltrating tumor foci. Therefore, reactive stroma-based biomarkers may potentiall
Externí odkaz:
https://doaj.org/article/66d29ef6886944868b4b67dd41cbe809
Autor:
Silvia Martini, Valentina Zuco, Monica Tortoreto, Stefano Percio, Elisa Campi, Rihan El Bezawy, Valentina Doldi, Yosef Landesman, Marzia Pennati, Nadia Zaffaroni
Publikováno v:
Pharmaceuticals, Vol 14, Iss 6, p 523 (2021)
Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expressi
Externí odkaz:
https://doaj.org/article/b5d9b2022b374d4caa774c33c5ffe47c
Autor:
Mara Lecchi, Maurizio Colecchia, C. Marenghi, Melanie Claps, Mario Catanzaro, Riccardo Valdagni, Valentina Doldi, Paolo Gandellini, Paolo Verderio, Rihan El Bezawy, Barbara Avuzzi, Nadia Zaffaroni, Tiziana Rancati, Fabio Badenchini, Chiara Maura Ciniselli, Elisa Campi
Publikováno v:
Cancers
Volume 13
Issue 10
Cancers, Vol 13, Iss 2433, p 2433 (2021)
Volume 13
Issue 10
Cancers, Vol 13, Iss 2433, p 2433 (2021)
Simple Summary Active surveillance (AS) has evolved as an alternative to radical treatment for potentially indolent prostate cancer. However, current selection criteria for entering AS are suboptimal, and a significant percentage of patients disconti
Autor:
Monica Tortoreto, Yosef Landesman, Stefano Percio, Valentina Zuco, Valentina Doldi, Elisa Campi, Rihan El Bezawy, Marzia Pennati, Nadia Zaffaroni, Silvia Martini
Publikováno v:
Pharmaceuticals, Vol 14, Iss 523, p 523 (2021)
Pharmaceuticals
Volume 14
Issue 6
Pharmaceuticals
Volume 14
Issue 6
Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expressi
Autor:
Daniele Rossini, Mirella Giordano, Carlotta Antoniotti, Nadia Zaffaroni, Chiara Cremolini, Beatrice Borelli, Alessandra Boccaccino, Alfredo Falcone, Marco Maria Germani, Elisa Sottotetti, Veronica Conca, Antonia Martinetti, Roberto Moretto, Gianluca Masi, Maria Antista, Francesca Corti, Gemma Zucchelli, Filippo Pietrantonio, Federica Marmorino, Elisa Campi
Publikováno v:
Journal of Clinical Oncology. 39:e15566-e15566
e15566 Background: Regorafenib is a treatment option for refractory mCRC patients with no validated predictors of benefit. We previously showed that, among several circulating angiogenic factors, low baseline Ang-2 and Tie-2 plasma levels were associ
Autor:
Sergio Villa, Paola Allavena, Riccardo Valdagni, Valentina Zuco, Nice Bedini, Elisa Campi, Alessandro Cicchetti, Federica Palorini, Samantha Pesce, S. Morlino, Nadia Zaffaroni, Barbara Avuzzi, Tiziana Rancati, Maria Emanuela Visentin, Tiziana Magnani, Marzia Pennati
Publikováno v:
Disease Markers
Disease Markers, Vol 2018 (2018)
Disease Markers, Vol 2018 (2018)
A recent “hot topic” in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previ
Autor:
Silvia L. Locatelli, Elisa Campi, Stefania Sbarra, Alessia Lopergolo, Carmelo Carlo-Stella, Alessandro M. Gianni, Marzia Pennati, Maria Grazia Daidone, Nadia Zaffaroni, Michelandrea De Cesare
Publikováno v:
International Journal of Cancer. 136:299-309
Because available treatments have limited efficacy in triple-negative breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed. In our study, we investigated the effects of the administrat
Autor:
Marzia, Pennati, Stefania, Sbarra, Michelandrea, De Cesare, Alessia, Lopergolo, Silvia L, Locatelli, Elisa, Campi, Maria Grazia, Daidone, Carmelo, Carlo-Stella, Alessandro M, Gianni, Nadia, Zaffaroni
Publikováno v:
International journal of cancer. 136(2)
Because available treatments have limited efficacy in triple-negative breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed. In our study, we investigated the effects of the administrat